Discover how color vision testing serves as a critical diagnostic tool for early detection and monitoring of glaucoma, macular degeneration, and other ocular diseases, potentially preserving vision and improving patient outcomes through timely intervention.
Color Vision Defects as Early Indicators of Glaucomatous Changes
Early detection of glaucoma is critical for preventing irreversible vision loss. Glaucoma is a group of eye conditions that damage the optic nerve, often due to elevated intraocular pressure (IOP). Since glaucoma typically progresses slowly and without noticeable symptoms in its early stages, many patients remain unaware of the disease until significant vision loss has occurred. Therefore, early detection and ongoing monitoring are essential for effective management and treatment of glaucoma.
Research has shown a significant correlation between acquired color vision defects and glaucoma. According to the study conducted by Papaconstantinou et al.i,patients with ocular hypertension (OH) and early glaucoma exhibited noticeable color vision deficiencies, particularly in the blue-yellow (tritan) spectrum. In their prospective study involving 99 eyes of 56 patients with OH, the researchers found that those who eventually developed glaucoma had significantly higher total error scores (TES) in color vision tests compared to those who did not progress to glaucoma.
These color vision changes were detectable before any significant visual field defects, as measured by standard Humphrey visual field (HVF) tests. This suggests that color vision testing can serve as an early indicator of glaucomatous changes, providing eye care professionals with a valuable tool for early diagnosis and intervention. The earliest significant changes in TES were observed as early as the first year of follow-up, highlighting the predictive value of incorporating color vision assessment into routine glaucoma screening protocols.
Detecting Acquired Tritan Deficiencies in Macular Disease and Diabetes
Acquired tritan deficiencies represent a critical diagnostic marker for macular disease and diabetic retinopathy. Research shows that at least 15% of the general population will acquire a tritan deficiency at some point in their lifeii; with some research reporting rates of acquired CVD as high as 45-66% in age groups 70 and olderiii. Unlike congenital color vision deficiencies that affect red-green discrimination, acquired tritan defects typically impact blue-yellow color perception (80% of the timeiv) and are strongly associated with retinal pathology affecting the outer retinal layers and photoreceptor function.
Conditions such as age-related macular degeneration (AMD)v, diabetic retinopathy, and medication toxicity frequently manifest with tritan deficiencies as an early sign of disease progression. The significance of tritan deficiencies in acquired disease lies in their sensitivity to changes in the macula and optic nerve before structural damage becomes apparent on imaging studiesvi. Regular color vision assessments can help identify early signs of macular changes in at-risk populations, enabling clinicians to monitor disease progression and adjust treatment plans accordingly (Figure 1).
Figure 1
Software charting monocular tritan (OS) visual ability degrading over time.
Monitoring Patients That have Macular Risks
Patients taking medications with known macular toxicity risks, such as hydroxychloroquine (Plaquenil), require systematic monitoring to detect early signs of retinal damagevii. Color vision testing provides a functional assessment that can identify subclinical changes before irreversible structural damage occursviii. This is particularly valuable for patients on long-term medication regimens where cumulative toxicity poses significant risk to retinal function.
Beyond medication monitoring, patients with systemic conditions affecting vascular health including diabetes, hypertension, and multiple sclerosis benefit from serial color vision assessments. Optic neuritis, frequently associated with multiple sclerosis, often presents with color vision deficits that may precede visual acuity loss. By incorporating color vision testing into comprehensive eye examinations for these at-risk populations, clinicians gain an additional functional metric that may reveal disease activity or progression earlier than traditional measures alone.
The integration of color vision testing with OCT imaging, visual fields, and other diagnostic technologies creates a comprehensive assessment framework. While OCT provides detailed structural information about retinal layers and optic nerve architecture, color vision testing offers complementary functional data about photoreceptor and neural pathway integrity. This multi-modal approach enhances diagnostic sensitivity and enables more nuanced clinical decision-making regarding treatment initiation, modification, or intensification.
Quantifying Color Vision Performance with Computerized Testing Technology
Computerized testing technology has transformed color vision assessment from a subjective screening process to a precise, quantifiable diagnostic procedure. The Waggoner CCVT offers reliable and quantifiable measures of color vision deficiencies, making it practical for clinical use. The system provides a comprehensive suite that can screen, diagnose, and track color vision performance in both pediatric and adult patients, with automated and randomized presentation of the plates that prevents test memorization and ensures consistent results across repeated administrations.
In a 2025 metanalysis of color vision tests, the Waggoner CCVT was ranked #1 in the detection of color vision deficienciesix and qualifies for reimbursement under CPT code 92283. This validation process included rigorous comparison studies demonstrating diagnostic accuracy and test-retest reliability comparable to traditional clinical standards. The computerized format provides several advantages over booklet-based tests, including standardized plate presentation time, plate order randomization, standardized illumination conditions, automated administration and scoring that eliminates examiner bias, as well as longitudinal test score tracking and charting. The WCCVT’s gated test logic starts with a screener, then, if a patient fails, it automatically provides two additional diagnostic sections which are eligible for reimbursement. The abbreviated test most patients receive takes ~2 minutes, while the full diagnostic can take up to 5 minutes.
The ability to quantify color vision performance with validated, precision testing technology enables clinicians to establish baseline measurements and track subtle changes over time. This longitudinal monitoring capability is particularly valuable for patients with progressive conditions or those undergoing treatment interventions where documenting objective improvement or stabilization supports clinical management decisions. Computerized testing improves consistency and long-term monitoring by providing standardized administration protocols and objective scoring metrics that facilitate comparison across visits and between providers.
Integrating Color Vision Testing into Clinical Practice for Enhanced Patient Outcomes
Integrating color vision testing into routine eye examinations can enhance early detection, improve monitoring of glaucoma and other ocular diseases, as well as add revenue for the practice through reimbursable diagnostic testing. The implementation process requires minimal workflow disruption, as computerized tests can be administered by trained technicians prior to the physician examination, similar to visual field or OCT testing protocols.
Tools like the Waggoner CCVT offer practical solutions for busy clinical environments, with test administration times typically ranging from three to five minutes depending on the specific protocol selected. The system generates comprehensive reports that document color vision performance with quantitative metrics suitable for medical record documentation and, when necessary, legal purposes such as driving license requirements or occupational qualification determinations. By adopting color vision testing into exam protocols, eye care professionals can improve patient outcomes through timely intervention and tailored treatment plans based on functional visual performance measures that complement structural diagnostic findings.
[i] Papaconstantinou, D., Georgalas, I., Kalantzis, G., Karmiris, E., Koutsandrea, C., Diagourtas, A., ... & Georgopoulos, G. (2009). Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma. Clinical Ophthalmology, 251-257.
[ii] Ivan, D. J. (2013). Ophthalmology. In R. B. Rayman (Ed.), Rayman’s clinical aviation medicine (5th ed., pp. 235–292). Castle Connolly Graduate Medical Publishing.
[iii], iv Haegerstrom-Portnoy, G., Schneck, M. E., Lott, L. A., Hewlett, S. E., & Brabyn, J. A. (2014). Longitudinal increase in anisometropia in older adults. Optometry and Vision Science, 91(1), 60–67. https://doi.org/10.1097/OPX.0000000000000114
[v] Fong, D. S., Barton, F. B., & Bresnick, G. H. (1999). Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American journal of ophthalmology, 128(5), 612–617. https://doi.org/10.1016/s0002-9394(99)00227-5
[vi] Jolly, J. K., Simunovic, M. P., Dubis, A. M., Josan, A. S., Robson, A. G., Bellini, M. P., Bloch, E., Georgiadis, O., da Cruz, L., Bridge, H., & MacLaren, R. E. (2021). Structural and Functional Characteristics of Color Vision Changes in Choroideremia. Frontiers in neuroscience, 15, 729807. https://doi.org/10.3389/fnins.2021.729807
[vii] Porter, D. (2020). What is Plaquenil? American Academy of Ophthalmology. https://www.aao.org/eye-health/drugs/what-is-plaquenil
[viii] Raju, P., & Yu, M. (2025). Clinical Applications of the Cone Contrast Test in Ophthalmology and Neurology. Journal of clinical medicine, 14(9), 3079. https://doi.org/10.3390/jcm14093079
[ix] Zhang, N., Yang, J., Hu, M., & Liu, Z. (2025). Diagnostic performance of color vision tests for color vision deficiency: A network meta-analysis on comparisons of multiple color vision tests. International Ophthalmology, 45(1), 208.